Get the latest news and updates
The vast majority of patients with cancer in the U.S. are treated at community hospitals and practices. It is therefore paramount that precision medicine oncology technologies that are rapidly becoming the standard of care for patients with advanced cancer be available to these facilities. Not only is there a delivery issue, there is a need to encourage the widespread uptake of precision genomics by community oncology practices. This will not only facilitate potentially better patient care but also aid in recruiting patients to clinical trials. However, considerable challenges exist in implementing a precision medicine programs, including administrative, logistic, and financial barriers. This session will feature community hospital representatives that will discuss their institution's experience and challenges with implementing precision medicine programs.
Dr. Pellini is Managing Partner of Section 32, a venture fund that invests in companies and inventors that are changing the way humans use technology and the way technology betters humanity. Previously, he served as CEO of Foundation Medicine (NASDAQ:FMI) from May 2011 until he transitioned to Chairman in February 2017. He currently serves as a member of the Board of Directors for Tango Therapeutics, Singular Genomics, Adaptive Biotechnologies, the Personalized Medicine Coalition, Thrive, and the Mission Hospital Foundation, in addition to his Board Chair position with Foundation Medicine. As a physician with more than 20 years of executive experience with companies at the forefront of clinical diagnostics and genomics, Dr. Pellini brings a breadth of understanding in personalized medicine, with a particular interest and focus on defeating cancer. Dr. Pellini is a member of the President’s Leadership Council at Thomas Jefferson University and Jefferson Health, as well as the Advisory Board for Mission Hospital’s Cancer Institute (Provident/St. Joseph Health). Dr. Pellini received a BA from Boston College, an MBA from Drexel University and an MD from Jefferson Medical College.
Dr. Adrian Lee has had a key role in shaping precision medicine research at the University of Pittsburgh and personalized care in the large UPMC integrated finance and delivery healthcare system. An example of the early progress in precision medicine is research and implementation of pharmacogenomics, and development of computational systems and architecture for sharing of clinical and genomic data. The goal of Dr. Lee’s laboratory is to translate basic cell and molecular research findings into the understanding and treatment of breast cancer. He is currently leading an effort to sequence metastatic breast cancers to identify vulnerabilities for novel precision therapies. Dr Lee has published over 160 peer reviewed research articles. In 2018 Dr. Lee was awarded the Terri L Chapman award from Susan G. Komen for the Cure, the PNC Elsie Hillman Distinguished Scholar award, and the University of Pittsburgh Biomedical Graduate Scholar Association (BGSA) Distinguished Mentor Award.